University of California Berkeley seal E. O. Lawrence Berkeley National Laboratory seal
The Carcinogenic Potency Project

3,3′-Dimethylbenzidine.2HCl (CAS 612-82-8)
SMILES, InChI and Structure are below.
Rats and Mice: Cancer Test Summary
Rat Target Sites Mouse Target Sites TD50 (mg/kg/day)
Male Female Male Female Rat Mouse
ezy lgi liv lun orc per pre ski smi cli ezy lgi liv lun mgl orc ski smi lun no positive 0.629m 28.6

Key to the Table Above

Positivity: For each chemical with a positive (carcinogenic) experiment in the Carcinogenic Potency Database (CPDB), results are included on carcinogenic potency (TD50) in each species and target sites in males and females. Positivity is determined by an author’s opinion in a published paper. If all experimental results in the CDPB are negative in a sex-species group, “no positive” appears. If the CPDB has no experiments in the sex-species group, “no test” appears. The summary presents the strongest evidence of carcinogenicity in each group. If there are both positive and negative experiments in a sex-species, the negative results are ignored in this Summary Table.
Target Site Codes:   cli = clitoral gland. ezy = ear/Zymbal’s gland. lgi = large intestine. liv = liver. lun = lung. mgl = mammary gland. orc = oral cavity (includes tissues of the mouth, oropharynx, pharynx, and larynx). per = peritoneal cavity. pre = preputial gland. ski = skin. smi = small intestine. Target sites are listed if any author of published experimental results concluded that tumors were induced in that organ by the test agent. If there is more than one positive experiment in a sex-species, target sites listed may be from more than one experiment, e.g. if liver and lung are both listed, then liver may have been a target in one experiment and lung in another.
TD50: Our standardized measure of carcinogenic potency, TD50, is the daily dose rate in mg/kg body weight/day to induce tumors in half of test animals that would have remained tumor-free at zero dose. Whenever there is more than one positive experiment in a species, the reported TD50 value is a Harmonic Mean calculated using the TD50 value from the most potent target site in each positive experiment.
Superscripts:   m = There is more than one positive experiment in the species, and TD50 values from each positive experiment are used in the calculation of the reported Harmonic mean of TD50.

The Carcinogenic Potency Database (CPDB) is a unique and widely used international resource of the results of 6540 chronic, long-term animal cancer tests on 1547 chemicals. The CPDB provides easy access to the bioassay literature, with qualitative and quantitative analyses of both positive and negative experiments that have been published over the past 50 years in the general literature through 2001 and by the National Cancer Institute/National Toxicology Program through 2004. The CPDB standardizes the diverse literature of cancer bioassays that vary widely in protocol, histopathological examination and nomenclature, and in the published author’s choices of what information to provide in their papers. Results are reported in the CPDB for tests in rats, mice, hamsters, dogs, and nonhuman primates.

For each experiment, information is included on species, strain, and sex of test animal; features of experimental protocol such as route of administration, duration of dosing, dose level(s) in mg/kg body weight/day, and duration of experiment; experimental results are provided on target organ, tumor type, and tumor incidence; carcinogenic potency (TD50) and its statistical significance; shape of the dose-response, author’s opinion as to carcinogenicity, and literature citation.

Only tests with dosing for at least ¼ the standard lifespan of the species and experiment length at least ½ the lifespan are included in the CPDB. Only routes of administration with whole body exposure are included. Doses are standardized, average dose rates in mg/kg/day. A description of methods used in the CPDB to standardize the diverse literature of animal cancer tests is presented for: 1) Criteria for inclusion of experiments 2) Standardization of average daily dose levels and 3) TD50 estimation for a standard lifespan. See Methods for other details.

TD50 provides a standardized quantitative measure that can be used for comparisons and analyses of many issues in carcinogenesis. The range of TD50 values across chemicals that are rodent carcinogens is more than 100 million-fold. More than half the chemicals tested are positive in at least one experiment.

A plot of all results on each experiment in the CPDB for this chemical is presented below. These results are the source information for the Cancer Test Summary table above.

3,3′-Dimethylbenzidine.2HCl: All Experiments and Citations in CPDB

The definition of each code in the plot below will appear in a pop-up window when the field name in the header line is clicked, e.g., Strain, Site, Path. Each numbered line starts a new experiment and reports protocol information in black. Average daily dose-rates per kg body weight per day are in green. Remaining lines report experimental results in blue.

Abbreviations of fields in header line: # = the line number in the plot of all CPDB chemicals; Xpo = duration of dosing; Xpt = duration of experiment; Site = tissue; Path = tumor type; DR = dose-response; AuOp = author’s opinion about carcinogenicity; LoConf, UpConf = confidence limits (99%) on TD50; Inc = tumor incidence for each dose group.

See Guide to reading the plot for details on each field, using an example of one experiment.

See Help to improve readability, or to fit the plot onto the screen or a printed page.



Chemical (Synonym) CAS
# Species Sex Strain Route Xpo+Xpt PaperNum        0 Dose  1 Dose 2 Dose  3 Dose          Literature Reference or NCI/NTP:Site Path
Site Path Notes   TD50  DR Pval    AuOp LoConf UpConf   Cntrl   1 Inc  2 Inc   3 Inc                                                        Brkly Code

3,3'-DIMETHYLBENZIDINE.2HCl 612-82-8 2329 M f bcn wat 52w52 1913m 0 1.00mg 1.80mg 3.60mg 7.00mg 14.0mg 28.0mg Schieferstein; fctx,27,801-806;1989 lun mix ekr 28.1mg * P<.2 8.34mg n.s.s. 0/16 1/15 2/16 1/13 3/16 0/16 4/16 lun adc ekr 147.mg * P<.2 24.0mg n.s.s. 0/16 0/15 0/16 0/13 0/16 0/16 1/16 2330 M f bcn wat 78w78 1913n 0 1.00mg 1.80mg 3.60mg 7.00mg 14.0mg 28.0mg lun adc ekr 168.mg * P<.2 36.9mg n.s.s. 0/21 0/23 1/20 1/21 0/20 0/21 2/18 lun mix ekr 295.mg * P<.8 23.8mg n.s.s. 4/21 1/23 8/20 5/21 4/20 2/21 5/18 2331 M f bcn wat 26m26 1913o 0 1.00mg 1.80mg 3.60mg 7.00mg 14.0mg 28.0mg lun mix er no dre P=1. 55.2mg n.s.s. 8/26 6/25 7/28 8/25 10/28 9/25 7/29 lun adc er no dre P=1. 115.mg n.s.s. 5/26 3/25 3/28 4/25 5/28 2/25 3/29 2332 M m bcn wat 52w52 1913m 0 .833mg 1.50mg 3.00mg 5.83mg 11.7mg 23.3mg lun adc ekr 123.mg * P<.3 20.0mg n.s.s. 0/15 0/16 0/14 0/14 0/15 1/16 0/16 lun mix ekr 684.mg * P<1. 8.25mg n.s.s. 1/15 3/16 1/14 5/14 2/15 4/16 2/16 2333 M m bcn wat 78w78 1913n 0 .833mg 1.50mg 3.00mg 5.83mg 11.7mg 23.3mg lun mix ekr 423.mg * P<1. 15.7mg n.s.s. 11/23 4/20 8/18 8/23 5/18 7/21 8/20 lun adc ekr no dre P=1. 60.0mg n.s.s. 0/23 0/20 0/18 2/23 0/18 0/21 0/20 2334 M m bcn wat 26m26 1913o 0 .833mg 1.50mg 3.00mg 5.83mg 11.7mg 23.3mg lun mix er 28.6mg * P<.002 + 14.0mg 168.mg 8/26 12/26 5/29 11/28 10/32 15/27 17/27 lun adc er 50.1mg * P<.002 + 24.3mg 278.mg 3/26 5/26 2/29 2/28 7/32 6/27 11/27 2335 R f f34 wat 60w60 TR390 : 0 1.71mg 4.00mg 8.57mg MXB MXB .418mg * P<.0005 .330mg .542mg 1/60 25/45 70/75 58/60 cli:ade,anb,car,cnb; col:adc,adp; duo:adc; ilm: adp,mua; jej:adc,adp,muc; liv:hpc,nnd; lun:a/a,a/c; mgl:adc; phr:sqc,sqp; rec:adc,adp; ski:bca,bcc, sqc,sqp; ton:sqc,sqp; zym:ade,anb,car,cnb. C cli MXA .847mg * P<.0005 c .634mg 1.16mg 0/60 14/45 42/75 32/60 cli:ade,anb,car,cnb. zym MXA 1.27mg * P<.0005 c .936mg 1.76mg 0/60 6/45 32/75 42/60 zym:ade,anb,car,cnb. cli MXA 1.31mg * P<.0005 .926mg 1.93mg 0/60 9/45 32/75 17/60 cli:ade,anb. S zym MXA 2.00mg Z P<.0005 1.42mg 2.90mg 0/60 2/45 22/75 35/60 zym:car,cnb. S cli MXA 2.58mg * P<.0005 1.66mg 4.23mg 0/60 5/45 11/75 18/60 cli:car,cnb. S zym MXA 3.08mg * P<.0005 1.88mg 5.43mg 0/60 4/45 11/75 12/60 zym:ade,anb. S ski MXA 3.17mg * P<.0005 c 1.91mg 5.75mg 0/60 3/45 9/75 12/60 ski:sqc,sqp. MXA MXA 3.20mg * P<.0005 c 1.92mg 5.76mg 0/60 3/45 9/75 13/60 phr:sqc,sqp; ton:sqc,sqp. ski MXA 3.80mg * P<.0005 c 2.22mg 7.20mg 0/60 3/45 10/75 9/60 ski:bca,bcc. MXA sqp 4.26mg * P<.0005 2.40mg 8.54mg 0/60 3/45 7/75 9/60 phr:sqp; ton:sqp. S ski sqc 5.56mg * P<.0005 2.87mg 13.1mg 0/60 2/45 4/75 7/60 S mgl MXA 5.77mg * P<.0005 2.81mg 22.3mg 2/60 2/45 7/75 6/60 mgl:adc,fba. S ski bca 5.77mg * P<.0005 2.95mg 15.5mg 0/60 3/45 5/75 5/60 S --- mnl 6.46mg * P<.002 e 3.09mg 33.1mg 1/60 3/45 6/75 4/60 MXA MXA 6.65mg * P<.0005 c 3.31mg 17.3mg 0/60 1/45 7/75 4/60 col:adc,adp; rec:adc,adp. liv MXA 6.97mg * P<.0005 c 3.41mg 17.7mg 0/60 0/45 7/75 4/60 liv:hpc,nnd. ski sqp 7.06mg * P<.0005 3.51mg 17.9mg 0/60 1/45 6/75 5/60 S MXA adp 7.11mg * P<.0005 3.45mg 19.6mg 0/60 1/45 6/75 4/60 col:adp; rec:adp. S liv nnd 7.62mg * P<.0005 3.60mg 21.2mg 0/60 0/45 7/75 3/60 S mgl adc 8.33mg * P<.0005 c 3.87mg 23.4mg 0/60 1/45 3/75 6/60 MXA MXA 11.0mg * P<.0005 c 5.01mg 37.5mg 0/60 1/45 3/75 5/60 duo:adc; ilm:adp,mua; jej:adc,adp,muc. ski bcc 11.6mg * P<.0005 5.21mg 37.6mg 0/60 0/45 5/75 4/60 S MXA sqc 11.8mg * P<.002 4.82mg 52.6mg 0/60 1/45 2/75 4/60 phr:sqc; ton:sqc. S lun MXA 11.9mg * P<.006 c 4.75mg 174.mg 1/60 1/45 3/75 4/60 lun:a/a,a/c. MXA MXA 15.4mg * P<.0005 6.37mg 56.1mg 0/60 0/45 2/75 5/60 duo:adc; ilm:mua; jej:adc,muc. S lun a/a 13.6mg * P<.02 5.07mg n.s.s. 1/60 1/45 3/75 3/60 S bra MXA 15.4mg * P<.06 e 5.67mg n.s.s. 0/60 2/45 2/75 1/60 bra:asl,mag,mnm. TBA MXB .462mg * P<.0005 .344mg .660mg 18/60 33/45 71/75 58/60 liv MXB 6.97mg * P<.0005 3.41mg 17.7mg 0/60 0/45 7/75 4/60 liv:hpa,hpc,nnd. 2336 R m f34 wat 58w60 TR390 : 0 1.48mg 3.45mg 7.50mg MXB MXB a .346mg Z P<.0005 .270mg .454mg 5/60 19/45 73/75 58/60 cec:adp; col:adc,adp,muc; duo:muc; ilm:adc,adp; jej:muc; lgi:adc; liv:hpc,nnd; lun:a/a,a/c; mul:msm; phr:sqc,sqp; pre:ade,car; rec:adc,adp; ski:bca, bcc,ker,sea,sqc,sqp; ton:sqc,sqp; zym:ade,anb,car,cnb. C ski MXA a .500mg Z P<.0005 c .380mg .672mg 0/60 11/45 54/75 30/60 ski:bca,bcc. ski bca a .534mg Z P<.0005 .405mg .723mg 0/60 10/45 52/75 29/60 S liv MXA a .898mg Z P<.0005 c .650mg 1.28mg 0/60 0/45 35/75 33/60 liv:hpc,nnd. zym MXA a 1.12mg Z P<.0005 c .806mg 1.59mg 1/60 3/45 32/75 36/60 zym:ade,anb,car,cnb. liv nnd a 1.12mg Z P<.0005 .789mg 1.66mg 0/60 0/45 29/75 26/60 S ski MXA a 1.55mg Z P<.0005 c 1.05mg 2.38mg 0/60 2/45 17/75 27/60 ski:sqc,sqp. zym MXA a 1.93mg Z P<.0005 1.30mg 2.98mg 0/60 2/45 21/75 23/60 zym:car,cnb. S zym MXA a 2.38mg Z P<.0005 1.48mg 4.22mg 1/60 1/45 13/75 16/60 zym:ade,anb. S liv hpc a 2.76mg Z P<.0005 1.65mg 5.02mg 0/60 0/45 12/75 12/60 S ski sqc a 2.80mg Z P<.0005 1.68mg 5.05mg 0/60 2/45 10/75 13/60 S ski sqp a 3.28mg Z P<.0005 1.93mg 6.04mg 0/60 0/45 8/75 15/60 S MXA MXA a 3.76mg Z P<.0005 c 2.18mg 7.05mg 0/60 0/45 6/75 15/60 cec:adp; col:adc,adp,muc; lgi:adc; rec:adc,adp. pre MXA a 3.96mg Z P<.0005 c 2.09mg 10.8mg 2/60 4/45 6/75 9/60 pre:ade,car. ski ker a 4.58mg Z P<.0005 c 2.34mg 12.4mg 1/60 1/45 8/75 5/60 MXA adp a 4.87mg Z P<.0005 2.58mg 10.4mg 0/60 0/45 6/75 9/60 cec:adp; col:adp; rec:adp. S lun MXA a 4.93mg Z P<.0005 c 2.47mg 13.2mg 1/60 0/45 8/75 6/60 lun:a/a,a/c. pre ade a 4.94mg Z P<.0005 2.43mg 16.8mg 2/60 4/45 4/75 8/60 S lun a/a a 5.47mg Z P<.0005 2.67mg 15.5mg 1/60 0/45 7/75 6/60 S ski sea a 5.62mg Z P<.0005 c 2.79mg 13.4mg 0/60 0/45 7/75 5/60 MXA MXA a 6.99mg Z P<.0005 c 3.39mg 16.6mg 0/60 0/45 4/75 8/60 duo:muc; ilm:adc,adp; jej:muc. MXA MXA a 7.79mg Z P<.0005 3.64mg 19.3mg 0/60 0/45 3/75 8/60 duo:muc; ilm:adc; jej:muc. S MXA MXA a 8.47mg Z P<.0005 c 3.80mg 23.9mg 0/60 0/45 4/75 5/60 phr:sqc,sqp; ton:sqc,sqp. ski bcc a 8.85mg * P<.002 3.67mg 43.0mg 0/60 1/45 4/75 2/60 S mul msm a 9.45mg Z P<.0005 c 3.95mg 31.6mg 0/60 0/45 3/75 4/60 amd pob a 10.6mg Z P<.003 4.22mg 78.6mg 0/60 2/45 1/75 3/60 S MXA MXA a 14.4mg Z P<.0005 6.16mg 45.9mg 0/60 0/45 0/75 7/60 col:adc,muc; lgi:adc; rec:adc. S MXA sqc a 26.7mg * P<.007 9.18mg 129.mg 0/60 0/45 1/75 3/60 phr:sqc; ton:sqc. S bra MXA a 26.1mg * P<.02 e 7.38mg n.s.s. 0/60 0/45 1/75 2/60 bra:gmf,mag,mnm. TBA MXB a .334mg Z P<.0005 .260mg .445mg 9/60 25/45 73/75 58/60 liv MXB a .898mg Z P<.0005 .650mg 1.28mg 0/60 0/45 35/75 33/60 liv:hpa,hpc,nnd.

Mutagenicity in Salmonella: positive
SMILES Code for 3,3′-Dimethylbenzidine.2HCl: C1(C2=CC(=C(N)C=C2)C)(=CC(=C(N)C=C1)C).[H]Cl.[H]Cl
InChI Code for 3,3′-Dimethylbenzidine.2HCl: InChI=1/C14H16N2.2ClH/c1-9-7-11(3-5-13(9)15)12-4-6-14(16)10(2)8-12;;/h3-8H,15-16H2,1-2H3;2*1H
Source for SMILES and InChI: USEPA Distributed Structure-Searchable Toxicity (DSSTox) Database
Chemical Structure for 3,3′-Dimethylbenzidine.2HCl: Chemical Structure
Source for structure: National Library of Medicine ChemIDPlus

See full CPDB Summary Table on 1547 chemicals. See Full CPDB for all results on 6540 experiments of 1547 chemicals.

A complete list of CPDB chemicals, which is searchable by name or by CAS number, is available here.

For a compendium of CPDB results organized by target organ, which lists all chemicals in each species that induced tumors in each of 35 organs, see Summary Table by Target Organ.

The CPDB is available in several formats that permit printing and downloading into spreadsheets and statistical databases.

  1. A plot of the CPDB presents results of 1547 experiments on 6540 chemicals in an easily readable format that has been used in publications of the CPDB.
  2. A Screen version plot for use on a single computer screen, with the same data.
  3. Excel version of the same data.
  4. Tab-separated versions of the same data, which can be easily read into databases.

A Supplementary Dataset gives details on dosing and survival for each experiment.

Relatively precise estimates of the lower confidence limit on the TD10 (LTD10) are readily calculated from the TD50 and its lower confidence limit, which are reported in the CPDB. For researchers and regulatory agencies interested in LTD10 values, we provide them in an Excel spreadsheet.

PDF versions of our publications of analyses using the CPDB are available, organized by year and by research topic.


Carcinogenic Potency Database Project (CPDB) Home Page
For more information about this Web Page, contact Specialized Information Services (tehip@teh.nlm.nih.gov).
Last updated: October 3, 2007


PDF documents are best viewed with the free Adobe® Reader http://get.adobe.com/reader
Excel documents are best viewed with the free Excel® Viewer http://www.microsoft.com/en-us/download/details.aspx?id=10